News
Empowering the biopharma industry with field-leading foundation models.
Recent News
Press
|
November 13, 2024
Genesis Therapeutics Announces New Equity Investment and Collaboration with NVIDIA to Optimize Key Computational Methods for AI-powered Drug Discovery
Business Wire
Press
|
September 10, 2024
Gilead and Genesis Therapeutics Announce Strategic Collaboration to Discover and Develop Novel Therapies
Business Wire
Press
|
September 10, 2024
Gilead partners with AI startup Genesis Therapeutics to make small molecule drugs
Endpoints News
Presentations & Publications
|
July 22, 2024
ICML Talk: Driving Small Molecule Drug Discovery with Generative Modeling
Press
|
April 2, 2024
CB Insights Names Genesis to AI 100: The most promising AI startups of 2024
CB Insights
Press
|
March 6, 2024
Fierce Medtech's Fierce 15 of 2023
Fierce Biotech
Press
|
March 6, 2024
Fierce Medtech Names Genesis Therapeutics a "Fierce 15" Company of 2023
Business Wire
Presentations & Publications
|
October 31, 2023
a16z's Bio Eats Health: Supercharging Discovery with Evan Feinberg
a16z
Join Us
Opportunities in AI and Physics Research
Our molecular AI research team is pioneering new frameworks for drug discovery, at the intersection of multi-dimensional ML models and physical simulation. See opportunities in software engineering, machine learning and computation chemistry.
Software Engineering
Machine Learning
Computational Chemistry
